ACADEMIC DRUG
DEVELOPMENT IN ONCOLOGY - TRANSLATING BASIC SCIENCE RESEARCH INTO INNOVATIVE TREATMENTS
16^th November 2011 in Berlin

Dear Colleagues,

 

We would like to take the opportunity to cordially invite you to attend the 3^rd AIO-Symposium „Academic Drug Development in Oncology - Translating Basic Science Research Into Innovative Treatments” on 16^th November 2011 in Berlin.

 

The meeting will be held at Pullman-Hotel Schweizerhof in the run-up of the 8^th AIO Autumn Congress which will take place from 17^th to 20^th November at the same venue.

 

The AIO (Working Group for Medical Oncology of the German Cancer Society) will arrange the meeting in cooperation with the their study group „Wirkstoffentwicklung / Frühe Phase I/II-Studien“, together with „Deutsches Krebsforschungszentrum (DKFZ)”, „Forschungsinstitut für Molekulare Pharmakologie (FMP)”, “Medizinische Hochschule Hannover (MHH)” and “Translations-Allianz in Niedersachsen (TRAIN)”.

Following the concept of the previous symposia we invited a number of renowned scientists who will present projects that aim at developing new therapies against cancer. For this symposium we decided to focus on three subjects. First we will discuss very recent developments in the field of mitosis research. Mitosis already constitutes one of the most important targets for anti-cancer drugs. However, based on the vast progress that has been made in the last few years on the molecular regulators of cell division new and more specific drugs will emerge and potentially revolutionize the way we treat tumors in the future.

 

The myc oncogene is one of the most important, if not the most important protein in the development of a wide variety of malignancies. For many years myc was seen as a potentially highly variable but undruggable target. We invited several experts in the field of myc research to discuss the question whether myc and the molecular pathways it regulates must still be seen as undruggable or if new possibilities of targeting this key component of oncogenesis will enter clinical medicine in the future.

 

Many of the new compounds that have been derived from academic or industrial research enter the clinical testing phase too slowly or do not live up to the expectations clinicians and patients have in later stage trials. Innovative phase 1 studies which help to unravel the potential and the risks of a new drug early on and might also guide the selection of the “right” patient to the “right” drug are highly needed. The third session of our symposium will therefore aim to show new strategies in phase 1 trial design thereby facilitating successful transition from laboratory to clinical drug research.

 

In addition we cordially invite everyone to submit abstracts on all aspects of academic drug development in oncology ranging from innovative targets, assay development and screening technology to new substances with activity in pre-clinical models or early clinical trials. We will choose several speakers from the abstract submissions who will get an opportunity to present their work as short talks. The remaining abstracts will be presented during the poster session.

 

We look forward to welcoming you on the occasion of the symposium on 16^th November 2011 in Berlin.

 

With best regards

 

Prof. Dr. Nisar Malek
For the AIO Arbeitsgruppe “Wirkstoffentwicklung / Frühe Phase I/II-Studien“

Abstract Deadline: 21^st October 2011

Please send your Abstract as a word file (.doc or .docx) to Brod@emc-event.com

Program

Registration form

Certification

The event is accredited as follows:
AIO – 6 Points / Landesärztekammer Berlin – 8 CME Points

Venue

Hotel Pullman Berlin Schweizerhof
Budapester Straße 25

10787 Berlin
Germany

Scientific Organizer

Prof. Dr. Nisar P. Malek
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie und Institut für Molekularbiologie
Carl-Neuberg-Str. 1
30625 Hannover
Germany

Fon: +49 (0)511 532-4585
Fax: +49 (0)511 532-4283
E-mail: Malek.Nisar@MH-Hannover.de

Congress-Office

AIO in der Deutschen Krebsgesellschaft e.V.
Straße des 17. Juni 106 – 108

10623 Berlin
Germany

 

Fon: +49 (0)30 322 932-933
Fax: +49 (0)30 322 932-943
E-mail: geschaeftsstelle@aio-portal.de
Internet: www.aio-portal.de

Authorised Congress Agency

EMC Event & Meeting Company GmbH
MCI - Munich Office

Ms. Julia Brod

Neumarkter Str. 21
81673 Munich
Germany

 

Fon: +49 (0)89 549096-74

Fax: +49 (0)89 549096-75

E-mail: Brod@emc-event.com

Bericht der Arbeitsgruppe vom November 2010

Unsere Arbeitsgruppe hat sich vor drei Jahren innerhalb der Arbeitsgemeinschaft Internistische Onkologie (AIO) gebildet, um die Überführung akademischer Grundlagen- forschungsprojekte in innovative onkologische Therapien zu ermöglichen. Um diesem Ziel gerecht zu werden, umfasst die AG Wissenschaftler und Mediziner aus verschiedensten Bereichen der bio-medizinischen Forschung, beginnend in der Molekularbiologie und Biochemie bis hin zur Strukturbiologie, organischen Chemie und natürlich der klinischen Onkologie.
Um Ihnen einen Einblick in die Arbeitsgebiete der Mitglieder der AG zu geben, haben wir ihre Lebensläufe in diesen Tätigkeitsbericht aufgenommen. Die transdisziplinäre Ausrichtung unserer Arbeitsgruppe hat, wie sie den Tätigkeitsberichten der Mitglieder entnehmen können, bereits zur Entdeckung mehrerer interessanter, neuer Wirkstoffkandidaten geführt. Diese Arbeiten werden in den nächsten Jahren fortgesetzt werden und hoffentlich zu innovativen Medikamenten zur Behandlung von Tumorerkrankungen führen.

top

Program

09.00	Welcome, U. Graeven, AIO
Session 1	Mitosis as a Target Chair: I. Hoffmann, Heidelberg
09.10 – 09.35	Chemical biology of cytokinesis U. Eggert, London
09.45 – 10.10	Targeting mitotic processes with small-molecule inhibitors A. Musacchio, Dortmund
10.20 – 10.50	Coffee Break
10.50 – 11.15	Plk1-related phosphoproteomics approaches to study cell division A. Santamaria, Basel
11.25 – 11.50	Chemical synthesis of new apoptosis-inducing agents addressing the colchicine binding site of Tubulin H.-G. Schmalz, Köln
12.00 – 13.30	Lunch and Poster Session

 

Session 2	Myc as a Target Chair: H. Oschkinat, Berlin
13.30 – 13.55	Small-molecule inhibitors of transcription factors T. Berg, Leipzig
14.05 – 14.30	From strategies and small molecules to target Myc for cancer therapy M. Eilers, Würzburg
14.40 – 15.05	Regulation of gene transcription by the MYC/MAX/MAD network B. Lüscher, Aachen
15.15 – 15.25	Short Talk 1
15.30 – 15.40	Short Talk 2
15.45 – 16.15	Coffee Break
Session 3	Innovative Concepts for Phase I / II Studies Chair: S. Hegewisch-Becker, Hamburg
16.15 – 16.40	Expectations of the Pharma Industry for Phase I & II Trials J. Stieglmaier, Nürnberg
16.50 – 17.15	Incorporation of biomarker development in early clinical trials – the right way forward? T. Arkenau, London
17.25 – 17.50	Phase I study design for molecular targeted drugs – need for a change? J. Drevs, Köln
18.00	Concluding remarks N. Malek

Chairs & Speakers:

	Dr. Hendrik-Tobias Arkenau LOC Leaders in Oncology Care, London
	Prof. Dr. Thorsten Berg Universität Leipzig, Institut für Organische Chemie
	Prof. Dr. Joachim Drevs Tumorzentrum UniSantus, Köln
	Prof. Dr. Ulrike Eggert King’s College, London
	Prof. Dr. Martin Eilers Universität Würzburg, Theodor-Boveri-Institute
	PD Dr. Ullrich Graeven Kliniken Maria Hilf, Mönchengladbach
	Prof. Dr. Susanna Hegewisch-Becker Internistische Praxisgemeinschaft Eppendorf, Hamburg
	PD Dr. Ingrid Hoffmann Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
	Prof. Dr. Bernhard Lüscher Universitätsklinikum Aachen, Institut für Biochemie und Molekularbiologie
	Prof. Dr. Nisar Malek Medizinische Hochschule Hannover
	Prof. Dr. Andrea Musacchio Max-Planck-Institut für molekulare Physiologie, Dortmund
	Prof. Dr. Hartmut Oschkinat, Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin
	Dr. Anna Santamaria Universität Basel, Biozentrum
	Prof. Dr. H.-G. Schmalz Universität Köln, Institut für Organische Chemie
	Dr. Julia Stieglmaier Novartis Pharma GmbH, Business Unit Oncology, Nürnberg
In Zusammenarbeit mit:

top